Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Our Technology

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

Learn More

Our Solutions

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Find out More

Radar™

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Discover Radar™

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

Find out More

InvisionFirst Lung - ctDNA Liquid Biopsy Test

Partnerships

Our Technology

Contact Us

Latest News and Events

Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

11 Jan 2022

Inivata, a leader in liquid biopsy, today announced that it has received the CE mark for its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC). In addition, Inivata has submitted to the MolDX program in the US for the reimbursement of RaDaR for clinical testing. Read More

More News

Liquid biopsies for residual disease and recurrence

22 Dec 2021

Jonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, Sarah-Jane Dawson, Esther Louise Moss, Ramaswamy Govindan, Iain Beehuat ... Read More

More Publications

LBx 2022

Event expiration date display - 10 - 11 FEB 2022

Location: San Diego, CA Read More

More Events

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives.

This is the story of the first patient Inivata tested.

Find out More

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

See our latest open roles

@inivata

January 19, 2022

We have a new white paper on RaDaR™, a highly sensitive & specific #ctDNA assay for the detection of molecular residual & recurrent disease (#MRD). To find out more about the #assay request a copy of the white paper here: https://www.inivata.com/about-us/contact-us/

January 18, 2022

We are proud to be partnering with the LBX #LiquidBiopsy Precision Oncology Summit in February. Join #TeamInivata & others in addressing the key challenges in progressing precision oncology pipelines by harnessing liquid biopsy technology.
Learn more here: https://lbx-summit.com/

January 17, 2022

Read our latest Med review titled ‘Liquid biopsies for residual disease and recurrence’ published in @CellCellPress